Abstract
This randomized controlled trial investigates the efficacy and safety of decaffeinated green tea polyphenols (DGTP) in reducing body fat and delaying the onset of precocious puberty in obese girls. The study found that 400 mg of daily DGTP significantly reduced body fat percentage and ovarian volumes, suggesting a potential non-pharmacological intervention for managing early sexual development driven by pediatric obesity.
Introduction
Precocious puberty—the early onset of sexual development—is a growing global health concern, particularly among girls. Obesity is a well-documented driver of this trend, as excess adipose tissue can trigger hormonal shifts that jumpstart the pubertal process. While green tea polyphenols (GTP) are known to aid weight loss in adults, their use in children has been limited due to concerns over caffeine-related side effects like anxiety and sleep disruption. This paper investigates whether a decaffeinated version (DGTP) can serve as a safe, non-pharmacological intervention to manage both pediatric obesity and the premature maturation of reproductive organs.
Methods
The researchers conducted a 12-week, double-blind, randomized controlled trial (RCT) involving obese girls aged 6–10 in Shanghai, China. Initially, 96 girls were screened, with 84 randomly assigned to either the intervention or control group.
- The Intervention: The experimental group received 400 mg/day of DGTP (standardized to 50% EGCG and <0.5% caffeine), while the control group received an identical-looking placebo of soybean oil.
- Standardization: Both groups received identical diet and exercise counseling from trained dietitians to isolate the effect of the supplement.
- Measurements: The team used bioelectrical impedance to measure body fat percentage (PBF) and B-scan ultrasonography to track the volume of the uterus and ovaries. Blood biomarkers, including sex hormones and serum uric acid, were also monitored.
Key Results
After controlling for confounders using multiple linear regression, the DGTP group showed significant metabolic and physiological improvements compared to the control group. One of the most striking findings was a decrease in ovarian volumes in the DGTP group—a "reversal" effect, as ovarian volume typically only increases as a girl approaches puberty.
Specific findings included:
- Body Fat: A significantly greater decrease in the percentage of body fat ($\beta$ = 2.932, 95% CI: 0.214 to 5.650).
- Uric Acid: A substantial drop in serum uric acid ($\beta$ = 52.601), a marker often elevated in metabolic syndrome.
- Ovarian Volume: Significant reductions in both right ($\beta$ = 1.881) and left ($\beta$ = 0.971) ovarian volumes.
- Safety Profile: By using decaffeinated extracts, the study reported zero adverse effects on sleep or heart rate, clearing a major hurdle for the use of tea-based supplements in pediatric care.
Discussion and Insights
The authors hypothesize that DGTP suppresses leptin expression in adipose tissue. Since leptin is a key signal that tells the brain the body has enough fat stores to begin puberty, suppressing it may be the mechanism behind the delayed development. This suggests DGTP provides a metabolic "edge" that lifestyle changes alone might not achieve in a short timeframe.
Limitations and Future Work
The study is a "preliminary explorer" with several limitations:
- Sample Size and Duration: Only 62 participants completed the 12-week intervention. A larger, multi-center trial is needed to confirm these effects.
- The "COVID Gap": The study had a 26.2% dropout rate, largely because the initial COVID-19 outbreak in early 2020 prevented many participants from attending their final follow-up.
- Long-term Outcomes: A 12-week window is too short to determine the final age of menarche or final adult height. Future research should focus on long-term follow-ups to see if these early physiological changes translate into meaningful health outcomes in adulthood.
Summary updated